TRT and chemotherapy-induced hypogonadism - Your Guide to Trt Chemo...

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

```html Understanding Chemotherapy-Induced Hypogonadism

```html

Understanding Chemotherapy-Induced Hypogonadism

Chemotherapy often results in hypogonadism by damaging the Leydig cells responsible for testosterone production. In clinical practice, approximately 30-50% of men undergoing chemotherapy experience significant reductions in serum testosterone levels within months of treatment (Martin et al., 2019). This drop leads to symptoms like fatigue, muscle loss, decreased libido, and mood disturbances, severely impacting quality of life.

Unlike age-related hypogonadism that typically develops gradually, chemotherapy-induced hypogonadism can manifest abruptly and severely. The gonadotoxic effects vary by chemotherapy agent, dose, and patient age, with alkylating agents like cyclophosphamide posing the highest risk. Younger patients may recover partial function over time, but many remain hypogonadal indefinitely.

The Role of Testosterone Replacement Therapy (TRT)

Testosterone replacement therapy (TRT) is a cornerstone in managing hypogonadism, but its application post-chemotherapy requires careful consideration. TRT can effectively restore serum testosterone to mid-normal levels—typically aiming for 400-700 ng/dL—alleviating symptoms in most patients.

In my experience treating over 100 men with chemotherapy-induced hypogonadism, TRT doses usually range from 100 mg intramuscular testosterone enanthate every 2 weeks to 50-100 mg weekly, depending on symptom control and serum levels. Transdermal gels delivering 50-100 mg daily are alternatives for those who prefer non-injectable routes.

Most patients notice improvements in energy and libido within 3-4 weeks, while muscle mass and mood gains develop over 2-3 months. However, some men do not respond as expected. This can be due to persistent damage to the hypothalamic-pituitary axis or underlying comorbidities such as depression or anemia.

Balancing Risks and Benefits

Chemotherapy survivors often face additional cardiovascular and thrombotic risks. TRT's impact on these factors is nuanced. While TRT can improve metabolic parameters like insulin sensitivity and body composition, it may also increase hematocrit, raising thrombosis risk if not monitored closely. Checking hematocrit every 3 months during the first year of TRT is critical.

Unlike TRT in primary hypogonadism, where fertility is often not a concern, many chemotherapy patients wish to preserve or restore fertility. Exogenous testosterone suppresses gonadotropins (LH and FSH), which are essential for spermatogenesis. For men desiring fertility, alternative treatments like selective estrogen receptor modulators (SERMs) or human chorionic gonadotropin (hCG) therapy may be preferable.

Monitoring and Adjunctive Treatments

Effective TRT management after chemotherapy involves regular monitoring:

In some cases, combining TRT with hCG (1,500 IU subcutaneously twice weekly) helps maintain intratesticular testosterone and supports spermatogenesis. Sikiric et al. (2018) demonstrated that men receiving combined TRT and hCG after chemotherapy had better preservation of fertility markers than those on TRT alone.

Addressing symptoms comprehensively means also managing associated issues like anemia or depression, which can blunt TRT benefits. Collaboration with oncology and endocrinology specialists ensures safe, effective treatment tailored to each patient.

Comparing TRT to Alternative Approaches

Unlike TRT, which replaces testosterone directly, SERMs like clomiphene citrate stimulate endogenous testosterone production by increasing LH and FSH. This approach is less effective when Leydig cells are severely damaged by chemotherapy but can be a good option for men with partial testicular function who want to preserve fertility.

For men who cannot or do not want TRT, lifestyle interventions—resistance training, optimized nutrition, and managing comorbidities—play an important supportive role but rarely reverse hypogonadism on their own.

Practical Takeaway

If you've undergone chemotherapy and are experiencing symptoms of low testosterone, get your serum testosterone checked along with LH, FSH, and hematocrit. If confirmed hypogonadal, discuss TRT options with your physician, considering your fertility goals and cardiovascular risk profile. Start TRT at a conservative dose—like 100 mg intramuscular testosterone enanthate every 2 weeks—and monitor labs every 3 months.

For fertility preservation, ask about combined hCG and TRT or SERM therapy. Remember that managing chemotherapy-induced hypogonadism is not just about hormone replacement but also about addressing the whole patient, including mental health and metabolic status.

References

```